MU: 17% | Micron shares are trading higher following better-than-expected Q4 financial results.

TBIO: 148% | Telesis Bio Partners With Beckman Coulter Life Sciences To Revolutionize DNA And mRNA Synthesis, Enabling Scalable, High-Fidelity Biofoundries Through Automated Gibson SOLA Enzymatic Reagent Platform

KTTA: 69% | Pasithea Therapeutics Announced Safety, Tolerability, Pharmacokinetic And Preliminary Efficacy Data From The First 2 Cohorts Of Patients In Its Phase 1 Clinical Trial Of PAS-004